Clinical trials: sponsored by Eli Lilly and Company
Overweight, Obesity
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese.
- Trial name
- NCT06606106
- Testing
- LY3537031
- Where
- 5 sites in United States
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Hepatic Insufficiency
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
The purpose of this study is to measure how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function and in healthy…
- Trial name
- NCT07165002
- Testing
- LY3537031
- Where
- 3 sites in Hungary, New Zealand and 1 more
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes.
- Trial name
- YKAA (NCT06945406)
- Testing
- LY4057996 SC, LY4057996 IV, Degludec SC
- Where
- Germany
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study of Eloralintide (LY3841136) in Healthy Participants
The main purpose of this study is to learn about safety, tolerability and how well the body processes two different eloralintide solutions.
- Trial name
- NCT07701083
- Testing
- Eloralintide
- Where
- 2 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study of Abemaciclib (LY2835219) in Healthy Participants
The main purpose of this study is to compare different forms of abemaciclib (LY2835219) to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects.
- Trial name
- NCT07818967
- Testing
- Abemaciclib Tablet (Test Formulation), Abemaciclib Tablet (Reference Formulation), Abemaciclib Oral Granules (Test Formulation)
- Where
- Singapore
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Remternetug (LY3372993) in Healthy Chinese Participants
The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants.
- Trial name
- NCT07346495
- Testing
- LY3372993
- Where
- 2 sites in China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4226695 in Healthy Participants
The main purpose of this study is to assess how well LY4226695 is tolerated and what side effects may occur in healthy participants.
- Trial name
- NCT07767487
- Testing
- LY4226695
- Where
- 2 sites in United States, Singapore
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants
The main purpose of this study is to compare how much and how quickly olomorasib gets into the bloodstream when it is taken in 2 different ways, and to check for any side effects.
- Trial name
- NCT07794592
- Testing
- Olomorasib test, Olomorasib reference
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight or Obesity, Healthy
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global.
- Trial name
- YHAA (NCT07152002)
- Testing
- LY4064912
- Where
- 3 sites in United States, Singapore
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Participants
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
- Trial name
- NCT06916143
- Testing
- LY4100511, Rabeprazole
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3526318 in Healthy Male Japanese Participants
This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to: Assess how safe and well tolerated LY3526318 is when given by mouth. Measure how LY3526318 affects the kidney and the liver.
- Trial name
- NCT05580250
- Testing
- LY3526318, Iohexol, Simvastatin
- Where
- Japan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants
The purpose of the study is to see how itraconazole affects LY4395089 in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
- Trial name
- NCT07592572
- Testing
- LY4395089, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Obesity
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity.
- Conditions
- Healthy, Obesity, Overweight
- Trial name
- NCT07232732
- Testing
- LY3549492
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study of LY4178256 in Healthy Participants
The main purpose of this study is to evaluate how well LY4178256 is tolerated and what side effects may occur in healthy participants.
- Trial name
- NCT07698210
- Testing
- LY4178256
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese.
- Trial name
- NCT07738614
- Testing
- Eloralintide, Acetaminophen
- Where
- 2 sites in United States, Singapore
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Liver Dysfunction, Healthy
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild…
- Trial name
- NCT06916078
- Testing
- Lepodisiran
- Where
- 4 sites in United States, Hungary
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Overweight
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits.
- Conditions
- Healthy, Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT06945419
- Testing
- LY4086940
- Where
- 5 sites in United States, Singapore
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Kidney Disease, Renal Insufficiency Chronic
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to…
- Conditions
- Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment
- Trial name
- NCT07426380
- Testing
- LY3841136
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4065967 in Healthy Participants
The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side…
- Trial name
- NCT07607483
- Testing
- LY4065967 Tablet, LY4065967 Formulated Capsule, LY4065967 Capsule
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2…
- Trial name
- NCT07765511
- Testing
- Macupatide, Eloralintide
- Where
- 3 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company